Search clinical trials for: erlotinib or gefitinib

Total 7029 results

Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
Novartis Pharmaceuticals

Withdrawn

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Carcinoma, Non-small Cell Lung
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Peking University Third Hospital

Unknown

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
Sichuan Provincial People's Hospital

Unknown

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (Hybrid)

Stage IV EGFR Mutated NSCL With Brain Metastases

China
Sichuan Provincial People's Hospital

Terminated

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) (Sindas)

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Sun Yat-sen University

Unknown

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study (GITIC)

Gastrointestinal Cancers

China
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Unknown

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Non-small Cell Lung Cancer

China
Samsung Medical Center
AstraZeneca

Unknown

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

EGFR Mutation Positive Non-small Cell Lung Cancer

Korea, Republic of
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China

Completed

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Cancer
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
National Cancer Center, Korea

Unknown

Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Eli Lilly and Company

Completed

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Lymphoma | Carcinoma, Non-Small-Cell Lung | Solid Tumors

Japan
First People's Hospital of Hangzhou

Unknown

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Lung Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
Kunming Medical University

Terminated

CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Qilu Hospital of Shandong University

Unknown

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer (TCL-1)

Non-Small-Cell Lung Cancer

China
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
University Hospital Regensburg

Completed

Psychometric Properties of the EORTC QLQ-LC29

Lung Cancer

Germany
Lady Davis Institute
Jewish General Hospital

Unknown

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (CURCUMIN)

Lung Cancer

Canada
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Hunan Province Tumor Hospital

Recruiting

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Tan Tock Seng Hospital
AstraZeneca; Singapore Cancer Syndicate.

Unknown

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Liver Cancer

Singapore
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (TP2001-201)

Recurrent Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
Clinical Research Center for Solid Tumor, Korea
Seoul National University Hospital; Korean Cancer Study Group

Terminated

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Leptomeningeal Carcinomatosis

Korea, Republic of
Memorial Sloan Kettering Cancer Center

Terminated

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Spain, Russian Federation, France, Bulgaria, Germany, Estonia, Italy, Poland, Taiwan, United Kingdom, Singapore, Ireland, Belgium
Dana-Farber Cancer Institute
Astellas Pharma Inc

Terminated

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.

Completed

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

United States
Ontario Clinical Oncology Group (OCOG)
Roche Pharma AG

Completed

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Non-small Cell Lung Cancer

Canada
Amsterdam UMC, location VUmc

Completed

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases

Netherlands
Guangdong Provincial People's Hospital

Unknown

Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases
David M. Jackman, MD
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital

Completed

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Non-small Cell Lung Cancer

United States
University of Alabama at Birmingham
Genentech, Inc.; OSI Pharmaceuticals

Completed

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer (UAB0718)

Head and Neck Cancer

United States
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NSCLC | EGFR Mutation

China
Henry Ford Health System
Genentech, Inc.

Terminated

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Head and Neck Cancer | Carcinoma, Squamous Cell
Oslo University Hospital

Terminated

Thoracal Radiotherapy and Tarceva (ThoRaT)

Cancer

Norway
Hoffmann-La Roche

Completed

A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

Australia, Hong Kong, Romania, Germany, Russian Federation, United Kingdom, Bulgaria, Malaysia, Latvia, Slovenia, Croatia, Brazil, Italy, Lithuania, India, Mexico, Singapore, Peru, Ukraine
AZ-VUB
Hoffmann-La Roche

Unknown

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Lung Neoplasms | Non-Small Cell Lung Cancer | Adenocarcinoma, Bronchiolo-Alveolar

Belgium

Search clinical trials for: erlotinib or gefitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations